This post now available at the Health Affairs Blog by Tricia Neuman, Jack Hoadley, and Juliette Cubanski discusses Sovaldi (sofosbuvir), an oral drug recently approved by the FDA for the treatment of chronic hepatitis C, and the potential impact of this long-awaited cure on Medicare spending and Part D premiums.  It is authored by the Foundation’s Tricia Neuman, Jack Hoadley of Georgetown University’s Health Policy Institute, and the Foundation’s Juliette Cubanski.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.